Search Results - Rob C. vanWijk

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Finding the right hazard function for time‐to‐event modeling: A tutorial and Shiny application by Rob C. VanWijk, Ulrika S. H. Simonsson

    Get full text
    Article


  2. 2

    Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations by Rob C. van Wijk, Rami Ayoun Alsoud, Hans Lennernäs, Ulrika S. H. Simonsson

    Published in Applied Sciences (2020-03-01)
    Get full text
    Article


  3. 3

    Pharmacokinetic analysis across studies to drive knowledge‐integration: A tutorial on individual patient data meta‐analysis (IPDMA) by Rob C. vanWijk, Marjorie Z. Imperial, Radojka M. Savic, Belén P. Solans

    Get full text
    Article


  4. 4

    Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic by Laurynas Mockeliunas, Rob C. van Wijk, Caryn M. Upton, Jonathan Peter, Andreas H. Diacon, Ulrika S. H. Simonsson

    Published in Vaccines (2024-03-01)
    Get full text
    Article


  5. 5

    Seasonal influence on respiratory tract infection severity including COVID‐19 quantified through Markov Chain modeling by Rob C. vanWijk, Laurynas Mockeliunas, Caryn M. Upton, Jonathan Peter, Andreas H. Diacon, Ulrika S. H. Simonsson

    Get full text
    Article


  6. 6

    Model‐informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy by Alan Faraj, Rob C. vanWijk, Linda Neuman, Shraddha Desai, Grant E. Blouse, Tom Knudsen, Ulrika S. H. Simonsson

    Get full text
    Article


  7. 7

    Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19 by Rob C. van Wijk, Laurynas Mockeliunas, Gerben van den Hoogen, Caryn M. Upton, Andreas H. Diacon, Ulrika S. H. Simonsson

    Published in Scientific Reports (2023-09-01)
    Get full text
    Article


  8. 8

    Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development by Laurynas Mockeliunas, Alan Faraj, Rob C. van Wijk, Caryn M. Upton, Gerben van den Hoogen, Andreas H. Diacon, Ulrika S. H. Simonsson

    Published in Frontiers in Pharmacology (2023-04-01)
    Get full text
    Article


  9. 9

    Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial by Caryn M. Upton, Rob C. van Wijk, Laurynas Mockeliunas, Ulrika S.H. Simonsson, Kirsten McHarry, Gerben van den Hoogen, Chantal Muller, Arne von Delft, Helene-Mari van der Westhuizen, Reinout van Crevel, Gerhard Walzl, Pedro M. Baptista, Jonathan Peter, Andreas H. Diacon

    Published in EClinicalMedicine (2022-06-01)
    Get full text
    Article


  10. 10

    Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium by Rob C. van Wijk, Ainhoa Lucía, Pavan Kumar Sudhakar, Lindsay Sonnenkalb, Cyril Gaudin, Eik Hoffmann, Bérénice Dremierre, Diana Angélica Aguilar-Ayala, Michael Dal Molin, Jan Rybniker, Stefano de Giorgi, Laura Cioetto-Mazzabò, Greta Segafreddo, Riccardo Manganelli, Giulia Degiacomi, Deborah Recchia, Maria Rosalia Pasca, Ulrika S.H. Simonsson, Santiago Ramón-García

    Published in iScience (2023-04-01)
    Get full text
    Article


Search Tools: